No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
79 |
4. Check minimum number of eventsNone |
79 |
5. Include endpoints |
89 |
6. Filter based on genotype QC (FinnGen only) |
88 |
Control definitions (FinnGen only)
- Control exclude
- E4_ENDOGLAND
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- E20-E35
- Name in latin
- Dysfunctio polyglandularis (endocrina)
Similar endpoints
↥List of similar endpoints to
Polyglandular dysfunction
based on the number of shared cases.
Similar with more cases:
- Disorders of other endocrine glands
- Endocrine, nutritional and metabolic diseases
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 523 | 320 | 196 |
| Only index persons | 419 | 270 | 149 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 38.73 | 38.37 | 38.89 |
| Only index persons | 35.72 | 35.52 | 36.08 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 88 | 58 | 30 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.01 |
| Median age at first event (years) | 34.74 | 37.72 | 28.98 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
No data
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 89
- Matched controls
- 890
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H02AB09
ATC
hydrocortisone; systemic
155.1
37.1
37
*
H02AA02
ATC
fludrocortisone; oral
+∞
37.1
33
*
105
Kela drug reimbursment
Adrenal cortical hypofunction
+∞
34.7
31
*
E10.9
ICD-10 Finland
Type 1 diabetes mellitus, Without complications
16.3
32.5
33
31
A10AE05
ATC
insulin detemir; parenteral
16.9
30.8
30
26
E31.00
ICD-10 Finland
APECED syndrome
+∞
28.7
26
*
E27.1
ICD-10 Finland
Primary adrenocortical insufficiency
+∞
28.7
26
*
H03AA01
ATC
levothyroxine sodium; systemic
9.9
27.3
53
115
A11CC03
ATC
alfacalcidol; systemic
66.7
25.1
28
6
106
Kela drug reimbursment
Hypoparathyroidism
+∞
22.9
21
*
A10AE04
ATC
insulin glargine; parenteral
9.9
22.6
33
50
A10AB05
ATC
insulin aspart; parenteral
10.3
22.4
31
44
103
Kela drug reimbursment
Diabetes, insulin-treated
8.0
22.0
48
114
A12AA04
ATC
calcium carbonate; oral
101.8
21.9
23
*
215
Kela drug reimbursment
Diabetes, non-insulin-treated
7.7
21.0
46
109
E31.08
ICD-10 Finland
Autoimmune polyglandular failure
+∞
18.4
17
*
E31.9
ICD-10 Finland
Polyglandular dysfunction, unspecified
+∞
17.2
16
*
A10AC01
ATC
insulin (human); parenteral
8.5
16.9
26
41
A11CC02
ATC
dihydrotachysterol; oral
+∞
15.0
14
*
E83.51
ICD-10 Finland
Hypocalcemia
178.0
14.9
15
*
T89
ICPC
Diabetes insulin dependent
12.0
13.4
25
28
E03.80
ICD-10 Finland
Hypothyroidism caused by autoimmune thyroiditis
44.5
12.7
15
*
SPAT1262
SPAT
Handing over of treatment supplies
5.8
12.6
29
68
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
4.8
12.1
43
145
A10AB04
ATC
insulin lispro; parenteral
12.7
11.8
21
21
D44.8
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Pluriglandular involvement
+∞
11.7
11
*
E31.1
ICD-10 Finland
Polyglandular hyperfunction
+∞
11.7
11
*
E10.1
ICD-10 Finland
Type 1 diabetes mellitus, With ketoacidosis
40.9
11.7
14
*
E31.8
ICD-10 Finland
Other polyglandular dysfunction
+∞
10.6
10
*
25810
ICD-8 Finland
Polyglandular dysfunction and other diseases of endocrine glands, Polyglandular dysfunction
+∞
10.6
10
*
A12AA06
ATC
calcium lactate gluconate; oral
+∞
10.6
10
*
2581B
ICD-9 Finland
Polyglandular dysfunction and related disorders, Other combinations of endocrine dysfunction[AUTOIMMUNE-POLYENDOCRINOPATHY-CANDIDOSIS-ECTOD DYST]
+∞
10.6
10
*
XCK10
NOMESCO Finland
Photography of fundus of eye
6.1
10.4
21
43
121
Kela drug reimbursment
Severe hypofunction of sexual glands
23.4
10.2
14
7
H04AA01
ATC
glucagon; nasal, parenteral
12.2
10.1
18
18
A07AA02
ATC
nystatin; oral
10.0
10.0
20
25
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
10.2
9.7
19
23
E31.0
ICD-10 Finland
Autoimmune polyglandular failure
+∞
9.5
9
*
E34.9
ICD-10 Finland
Endocrine disorder, unspecified
+∞
9.5
9
*
25510
ICD-8 Finland
Diseases of adrenal glands, Adrenal cortical hypofunction
+∞
9.5
9
*
2581A
ICD-9 Finland
Polyglandular dysfunction and related disorders, Other combinations of endocrine dysfunction[SYNDROMA SCHMIDT]
+∞
9.5
9
*
WZC00
NOMESCO Finland
Treatment plan or consultation
4.0
9.4
50
218
A10AB01
ATC
insulin (human); parenteral
9.3
9.2
19
25
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
3.9
9.2
45
185
H36.09*E10.3
ICD-10 Finland
Insulin-dependent diabetes mellitus - Diabetic retinopathy
27.4
9.2
12
5
A01AB09
ATC
miconazole; local oral
5.8
9.1
19
40
A49.9
ICD-10 Finland
Bacterial infection, unspecified
5.4
8.9
20
45
107
Kela drug reimbursment
Pernicious anaemia
55.7
8.9
10
*
E83.50
ICD-10 Finland
Hypercalcemia
55.7
8.9
10
*
E10.7
ICD-10 Finland
Type 1 diabetes mellitus, With multiple complications
14.8
8.7
14
11
104
Kela drug reimbursment
Thyroid insufficiency
7.7
8.6
20
32
E31.01
ICD-10 Finland
Schmidt's syndrome
+∞
8.5
8
*
E21.09
ICD-10 Finland
Other primary hyperparathyroidism
+∞
8.5
8
*
E03.9
ICD-10 Finland
Hypothyroidism, unspecified
4.7
8.4
23
61
E87.1
ICD-10 Finland
Hypo-osmolality and hyponatraemia
13.6
8.4
14
12
E10.00
ICD-10 Finland
Insulin-dependent diabetes diabetic hypoglycemic coma
37.1
8.3
10
*
J02AB02
ATC
ketoconazole; oral
24.8
8.2
11
5
C03CA01
ATC
furosemide; systemic
3.8
7.9
33
120
E03.89
ICD-10 Finland
Other specified hypothyroidism
11.6
7.9
14
14
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
4.9
7.8
20
50
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
9.0
7.8
16
21
J18.9
ICD-10 Finland
Pneumonia, unspecified
3.8
7.8
31
109
J01MA12
ATC
levofloxacin; systemic
4.1
7.7
26
81
Z01.8
ICD-10 Finland
Other specified special examinations
3.8
7.7
30
104
B03BA03
ATC
hydroxocobalamin; parenteral
12.4
7.6
13
12
E13.9
ICD-10 Finland
Other specified diabetes mellitus, without complications
87.0
7.5
8
*
WX002
NOMESCO Finland
Sedation and analgesia
4.2
7.5
24
72
E27.2
ICD-10 Finland
Addisonian crisis
+∞
7.4
7
*
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
+∞
7.4
7
*
101
Kela drug reimbursment
Anterior pituitary hypofunction
+∞
7.4
7
*
133
Kela drug reimbursment
Severe chronic pancreatic insufficiency
22.2
7.3
10
5
SBA00
NOMESCO Finland
Microbiological examinations
22.2
7.3
10
5
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
4.3
7.3
22
63
Z31.5
ICD-10 Finland
Genetic counselling
8.8
7.3
15
20
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.3
7.3
47
224
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
4.9
7.2
18
44
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
3.8
7.1
27
91
SFA40
NOMESCO Finland
Restoration involving the entire crown of the tooth
3.8
7.1
27
91
TPH04
NOMESCO Finland
Cathetrisation of vein
3.7
6.9
27
93
B37.08
ICD-10 Finland
Other candidal stomatitis
43.5
6.9
8
*
E10.3
ICD-10 Finland
Type 1 diabetes mellitus, With ophthalmic complications
8.0
6.9
15
22
WZB00
NOMESCO Finland
Telephone prescription or other care instructions
3.2
6.8
44
208
E87.6
ICD-10 Finland
Hypokalaemia
11.3
6.8
12
12
A01AB04
ATC
amphotericin B; local oral
9.3
6.6
13
16
CL2S4
NOMESCO Finland
Ocular fundus photography for diabetic retinopathy screening
15.9
6.6
10
7
F31.7
ICD-10 Finland
Bipolar affective disorder, currently in remission
75.0
6.5
7
*
A09AA02
ATC
multienzymes (lipase, protease etc.); oral
12.3
6.5
11
10
WX882
NOMESCO Finland
High dependency care
19.8
6.4
9
5
E10.2
ICD-10 Finland
Type 1 diabetes mellitus, With renal complications
28.9
6.3
8
*
K29.4
ICD-10 Finland
Chronic atrophic gastritis
28.9
6.3
8
*
E16.2
ICD-10 Finland
Hypoglycaemia, unspecified
28.9
6.3
8
*
E10.4
ICD-10 Finland
Type 1 diabetes mellitus, With neurological complications
28.9
6.3
8
*
F31.9
ICD-10 Finland
Bipolar affective disorder, unspecified
28.9
6.3
8
*
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
7.7
6.3
14
21
A10AE06
ATC
insulin degludec; parenteral
7.7
6.3
14
21
25219
ICD-8 Finland
Diseases of parathyroid gland, Hypoparathyreoidismus alius sive NUD
+∞
6.3
6
*
H01AC01
ATC
somatropin; parenteral
+∞
6.3
6
*
E20.8
ICD-10 Finland
Other hypoparathyroidism
+∞
6.3
6
*
SPAT1225
SPAT
Implementation of podiatry rehabilitation plan
+∞
6.3
6
*
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
3.4
6.3
29
111
XF400
NOMESCO Finland
ECG with 12 standard connections
3.9
6.2
21
65
B01AB05
ATC
enoxaparin; parenteral
3.1
6.1
35
152
H3600, E103,
ICD-10 Finland
16.5
6.0
9
6
Z01.0
ICD-10 Finland
Examination of eyes and vision
3.5
6.0
26
95
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
28
46
8.42
17.62
17.2
3.0
1.21
1.23
mmol/l
0.66
28
40
72
299
8.37
17.31
32.7
9.4
1.18
1.22
mmol/l
2.03
61
256
50
177
5.16
13.54
7.1
3.9
17.11
8.94
mg/mmol
0.43
33
108
20
35
7.08
11.59
11.3
8.7
26.18
25.35
mmol/l
0.25
20
35
29
76
5.18
11.01
6.3
2.2
21.59
21.59
%
0.00
24
64
59
272
4.47
10.61
15.6
12.4
1.25
1.20
inr
0.19
26
84
52
229
4.06
9.75
4.2
1.9
98.60
100.57
pmol/l
0.11
36
109
21
51
5.08
8.55
7.0
7.1
5.86
5.79
kpa
0.12
21
51
26
76
4.42
8.45
8.1
9.3
102.85
103.91
mmol/l
0.48
26
76
15
15
11.76
8.41
10.3
1.4
5.28
5.02
kpa
0.48
15
15
12
11
12.38
7.04
5.6
1.7
25.41
25.82
mmol/l
0.06
12
11
10
6
18.52
6.92
7.2
3.7
2.06
1.12
nmol/l
—
10
6
41
188
3.19
6.63
1.9
1.4
0.88
2.08
u/ml
0.52
12
48
20
61
3.94
6.01
4.1
3.1
—
—
—
0
0
8
5
17.36
5.52
4.6
1.4
—
—
—
0
0
13
26
5.67
4.86
6.5
7.8
25.42
23.79
mmol/l
0.99
13
26
43
234
2.62
4.72
7.8
2.8
—
—
—
0
0
25
103
2.98
4.65
3.6
1.8
—
—
—
0
0
9
13
7.56
4.28
1.7
2.5
—
—
—
0
0
6
5
12.72
3.82
1.7
1.2
—
—
—
0
0
8
12
7.20
3.76
10.3
1.5
60.00
57.17
%
—
8
12
41
239
2.33
3.67
5.6
3.8
25.66
23.12
ng/l
0.14
32
144
16
58
3.14
3.65
10.1
17.4
115.50
123.03
g/l
0.90
16
58
36
200
2.34
3.58
6.0
3.9
0.00
0.00
estimate
-0.00
18
73
13
42
3.45
3.53
1.7
1.5
—
—
—
0
0
30
160
2.32
3.23
3.3
3.6
1227.17
844.01
ng/l
0.46
24
138
10
25
4.37
3.20
8.3
4.2
61.97
51.42
%
—
10
25
9
21
4.64
3.09
1.3
1.1
—
—
—
0
0
7
12
6.22
3.08
3.4
1.8
—
—
—
0
0
5
5
10.48
3.01
4.4
1.2
12.40
16.94
ug/l
—
5
5
7
13
5.74
2.93
3.4
2.0
—
—
—
0
0
10
29
3.75
2.79
5.3
7.6
2.01
1.06
%
—
10
29
10
29
3.75
2.79
4.0
7.6
0.76
0.73
%
—
10
29
10
29
3.75
2.79
2.2
1.6
—
—
—
0
0
7
14
5.33
2.78
3.4
1.9
—
—
—
0
0
7
14
5.33
2.78
1.4
7.4
—
—
—
0
0
12
43
3.07
2.77
9.8
8.3
1.36
1.65
%
0.31
12
43
6
10
6.34
2.74
1.7
1.0
—
—
—
0
0
12
42
3.14
2.67
9.8
8.5
0.74
0.77
%
0.09
12
42
7
15
4.97
2.65
3.4
1.9
—
—
—
0
0
10
31
3.50
2.61
17.5
3.4
25.45
25.56
mmol/l
—
10
31
29
166
2.11
2.57
3.1
1.7
1.28
1.24
mg/l
0.03
23
127
9
26
3.73
2.56
7.9
6.2
23.22
24.60
mmol/l
—
9
26
7
16
4.65
2.53
1.1
1.3
—
—
—
0
0
10
33
3.28
2.45
6.1
9.0
118.10
128.88
g/l
—
10
33
5
8
6.54
2.40
1.0
1.0
—
—
—
0
0
8
23
3.71
2.33
3.1
2.0
—
—
—
0
0
8
24
3.56
2.24
3.9
2.3
—
—
—
0
0
6
14
4.51
2.19
4.0
1.9
—
—
—
0
0
45
316
1.86
2.15
3.4
2.8
—
—
—
0
0
7
20
3.71
2.10
11.1
1.7
4.33
3.77
mmol/l
—
7
20
82
724
2.68
2.07
47.0
14.1
3.95
3.94
mmol/l
0.09
82
707
82
721
2.74
2.07
46.9
14.0
139.29
139.64
mmol/l
0.53
82
704
15
72
2.30
2.00
3.0
1.7
—
—
—
0
0
37
254
1.78
1.84
3.7
2.9
36.84
30.40
u/l
0.57
37
242
6
18
3.49
1.78
4.0
1.8
—
—
—
0
0
6
18
3.49
1.78
4.0
1.8
—
—
—
0
0
7
24
3.08
1.76
3.4
2.7
3.97
3.72
g/l
—
7
24
14
69
2.22
1.76
3.1
1.6
—
—
—
0
0
40
284
1.74
1.75
6.7
3.7
—
—
—
0
0
47
357
1.67
1.56
7.7
5.2
0.00
0.00
estimate
-0.00
19
72
5
15
3.47
1.54
3.8
2.5
23.40
27.50
ug/min
—
5
8
9
37
2.59
1.53
1.6
1.2
—
—
—
0
0
47
361
1.64
1.47
6.4
3.9
0.00
0.04
estimate
0.49
17
69
47
361
1.64
1.47
6.4
3.8
0.00
0.00
estimate
-0.00
20
77
5
16
3.25
1.46
2.0
1.8
—
—
—
0
0
5
17
3.05
1.38
2.6
2.6
—
—
—
0
0
18
117
1.67
1.04
4.1
4.3
1.00
1.89
ug/l
2.13
18
105
22
153
1.58
0.98
3.7
2.2
—
—
—
0
0
73
655
1.64
0.97
33.2
15.4
15.23
14.40
%
0.67
73
650
6
27
2.31
0.95
5.3
2.2
76.33
92.00
%
—
6
27
6
27
2.31
0.95
3.5
1.3
52.67
33.07
nmol/l
—
6
27
6
27
2.31
0.95
1.2
1.1
—
—
—
0
0
6
31
2.00
0.86
1.5
1.6
—
—
—
0
0
9
141
0.60
0.78
2.0
2.3
—
—
—
0
0
5
24
2.15
0.76
1.2
1.3
—
—
—
0
0
5
24
2.15
0.76
9.0
2.8
233.80
198.42
%
—
5
24
16
110
1.55
0.75
2.8
2.7
0.10
1.07
e6/l
3.62
11
63
5
25
2.06
0.74
1.8
2.1
—
—
—
0
0
7
40
1.81
0.73
3.4
2.1
0.01
0.04
e6/l
—
7
40
15
104
1.53
0.68
3.1
2.9
1.10
4.86
e6/l
—
10
57
0
20
0.00
0.61
0.0
1.1
—
2.84
—
0
12
12
81
1.56
0.61
2.6
2.4
6.33
4.45
umol/l
0.60
12
72
7
47
1.53
0.49
1.1
1.0
—
—
—
0
0
9
128
0.67
0.47
1.8
2.2
—
—
—
0
0
14
180
0.74
0.42
2.1
1.6
—
—
—
0
0
77
734
1.36
0.38
34.1
12.7
16.45
21.22
mg/l
1.18
69
555
73
693
1.30
0.36
33.0
10.3
85.54
88.27
ml/min/173m2
0.35
68
557
18
149
1.26
0.31
1.9
1.5
—
—
—
0
0
82
835
0.77
0.31
49.5
18.9
129.06
136.47
g/l
4.82
82
827
16
131
1.27
0.30
1.4
1.3
1.18
8.02
u/ml
—
6
66
60
565
1.19
0.27
3.5
3.5
—
—
—
0
0
70
726
0.83
0.23
8.0
4.3
2.54
2.83
mmol/l
1.69
65
678
10
84
1.21
0.14
23.8
8.1
—
—
—
0
0
70
715
0.90
0.09
7.6
4.0
4.53
4.73
mmol/l
0.88
65
672
70
712
0.92
0.06
7.4
4.0
1.60
1.50
mmol/l
0.87
65
668
68
682
0.99
0.00
6.6
3.6
1.22
1.23
mmol/l
0.04
63
635
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
7
0.00
0.00
0.0
4.9
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
13.50
—
0
6
0
8
0.00
-0.00
0.0
4.0
—
138.71
—
0
8
0
5
0.00
-0.00
0.0
1.0
—
0.31
—
0
5
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
10.01
—
0
5
0
5
0.00
-0.00
0.0
1.4
—
86.20
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint E4_DYSPOLYGL and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have E4_DYSPOLYGL.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: E4_DYSPOLYGL – Polyglandular dysfunction
GWS hits: 2
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data